Page last updated: 2024-12-05

cytisine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cytisine is an alkaloid found in the seeds of the laburnum tree (Laburnum anagyroides) and other plants of the genus Cytisus. It is a nicotinic acetylcholine receptor agonist, meaning it mimics the effects of acetylcholine at these receptors. Cytisine is currently being investigated as a potential smoking cessation aid. It is thought to work by stimulating the same receptors in the brain that are activated by nicotine, thus reducing cravings and withdrawal symptoms. Several studies have shown that cytisine is effective in helping smokers quit, with a similar success rate to varenicline. However, further research is needed to fully understand the safety and efficacy of cytisine. Cytisine is also being studied for its potential therapeutic effects in other conditions, such as Alzheimer's disease, Parkinson's disease, and ADHD.'

FloraRankFlora DefinitionFamilyFamily Definition
LaburnumgenusA plant genus of the family FABACEAE named after the drooping clusters of flowers.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
FabaceaefamilyThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID10235
CHEMBL ID497939
CHEBI ID4055
SCHEMBL ID161398
MeSH IDM0045860

Synonyms (121)

Synonym
smr001233264
MLS002153916
HMS3267D20
BRD-K74186897-001-02-5
AKOS015833102
einecs 207-616-0
brn 0083882
1,5-methano-8h-pyrido(1,2-a)(1,5)diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1r,5s)-
hsdb 3560
1,2,3,4,5,6-hexahydro-1,5-methano-8h-pyrido(1,2-a)(1,5)diazocin-8-one
nsc 407282
PRESTWICK3_000624
cytisine (-)
PRESTWICK_140
tocris-1390
NCGC00025138-01
cas-485-35-8
tnp00030
NCGC00017171-01
NCGC00016463-01
NCGC00179513-01
BPBIO1_000648
BSPBIO_000588
citizin
1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1r)-
NSC407282 ,
ulexin
laburnin
mls003171607 ,
ulexine
1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-
tsitizin
sophorine
tabex
1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1r-cis)-
cytitone
tabax
baptitoxine
baptitoxin
cytizin
cytisine ((+)-)
nsc-407282
cystisine
wln: t c666 a gvn lm&ttj
cytiton
cytisine ,
485-35-8
cytisine, >=99%, powder
NCGC00025138-02
c11h14n2o
PDSP1_000461
citizine
cystisin
(1r,9s)-7,11-diazatricyclo[7.3.1.0~2,7~]trideca-2,4-dien-6-one
bdbm50143282
(1r,9s)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
(1r,5s)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
AKOS000276818
cytisinicline
chebi:4055 ,
6039 sopharma
CHEMBL497939 ,
MLS002222174
HMS2096N10
(1r,5s)-3,4,5,6-tetrahydro-1h-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2h)-one
HMS2235L06
NCGC00016463-02
NCGC00016463-04
NCGC00016463-03
baphitoxine
unii-53s5u404nu
5-24-02-00535 (beilstein handbook reference)
53s5u404nu ,
cytisinicline [usan]
(1r,5s)-1,2,3,4,5,6-hexahydro-1,5-methano-8h-pyrido[1,2a][1,5]diazocin-8-one
cytisin
(1r,5s)-1,2,3,4,5,6-hexahydro-1,5-methano-8h-pyrido[1,2-a][1,5]diazocin-8-one
(1r,5s)-1,2,3,4,5,6-hexahydro-8h-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one
c5e ,
cytisine [hsdb]
(1r,5s)-1,2,3,4,5,6-hexahydro-1,5-methano-8h-pyrido-(1,2-a)(1,5)diazocin-8-one
cytisinicline [who-dd]
cytisine [mart.]
(1r,5s)-1,2,3,4,5,6-hexahydro-8h-1,5-methanopyrido(1,2-a)(1,5)diazocin-8-one (cytisine)
cytisine [mi]
cytisinicline [inn]
S2287
(1r,9s)-7,11-diazatricyclo[7.3.1.0^{2,7}]trideca-2,4-dien-6-one
gtpl5347
CCG-208621
SCHEMBL161398
1,5-methano-8h-pyrido[1,2-a][1,5]diazocin-8-one, 1,2,3,4,5,6-hexahydro-, (1r,5s)-
AC-34317
F9994-5373
(1r,5s)-1,2,3,4,5,6-hexahydro-1,5-m ethano-8h-pyrido[1,2-a][1,5]diazocin-8-one
HB2033
DB09028
cytisine, >=99.0% (hplc), >=99%
SW219952-1
Q417343
HY-N0175
CS-0007888
ANJTVLIZGCUXLD-DTWKUNHWSA-N
HMS3678L21
115051-74-6
AS-19539
HMS3414N03
BRD-K74186897-001-13-2
BRD-K74186897-001-04-1
HMS3884L11
DTXSID00883395
(1r,9s)-7,11-diazatricyclo[7.3.1.0,2,7]trideca-2,4-dien-6-one
EN300-224852
BC164343
cytisine- bio-x
cytisiniclinum
cytisine (mart.)
citisiniclina
(1r)-1,2,3,4,5,6-hexahydro-1,5-methano-8h-pyrido-(1,2-a)(1,5)diazocin-8-one
(1r,5s)-1,2,3,4,5,6-hexahydro-8h-1,5-methanopyrido(1,2-a)(1,5)diazocin-8-one
Z1203159860

Research Excerpts

Overview

Cytisine (CYT) is a quinolizidine alkaloid used for nicotine addiction treatment. Cytisine is a partial agonist of some nAChRs and has been used for smoking cessation.

ExcerptReferenceRelevance
"Cytisine is a prospective pharmacological alternative for community pharmacy smoking cessation services. "( Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.
Boonsawat, W; Dilokthornsakul, P; Hansuri, N; Lertsinudom, S; Phusahat, P; Tawinkan, N; Theeranut, A; Zaeoue, U, 2022
)
2.47
"Cytisine derivatives are a group of alkaloids containing the structural core of cytisine, which are mainly distributed in Fabaceae plants with a wide range of pharmacological activities, such as resisting inflammation, tumors, and viruses, and affecting the central nervous system. "( [Research progress on chemical structures and pharmacological effects of natural cytisine and its derivatives].
Xie, XY; Xu, JB; Zhan, ZJ; Zhang, YX; Zhou, QQ; Zhou, W, 2023
)
2.58
"Cytisine is a smoking cessation medication. "( Cytisine for smoking cessation: A systematic review and meta-analysis.
Dennis, BB; Devereaux, PJ; Fairbairn, N; Lu, C; Mbuagbaw, L; Ofori, S; Olasupo, OO, 2023
)
3.8
"Cytisine (CYT) is a quinolizidine alkaloid used for nicotine addiction treatment. "( Development and Validation of LC-MS/MS Method for Determination of Cytisine in Human Serum and Saliva.
Buszewski, B; Courtney, RJ; Szultka-Młyńska, M; Tutka, P; Wróblewski, K, 2023
)
2.59
"Cytisine is a partial agonist of some nAChRs and has been used for smoking cessation."( Probing Binding Interactions of Cytisine Derivatives to the α4β2 Nicotinic Acetylcholine Receptor.
Blom, AEM; Campello, HR; Dougherty, DA; Gallagher, T; Lester, HA, 2019
)
1.52
"Cytisine is a quinolizidine alkaloid isolated from various Leguminosae plants. "( Advances on the Bioactivities, Total Synthesis, Structural Modification, and Structure-Activity Relationships of Cytisine Derivatives.
Huang, X; Xu, H, 2020
)
2.21
"Cytisine is a natural product isolated from plants and is a member of the quinolizidine alkaloid family. "( Cytisine exerts anti-tumour effects on lung cancer cells by modulating reactive oxygen species-mediated signalling pathways.
Cao, LK; Jin, CH; Li, SM; Li, TZ; Luo, YH; Piao, XJ; Wang, C; Wang, H; Wang, JR; Xu, WT; Xue, H; Zhang, T; Zhang, Y, 2020
)
3.44
"Cytisine is a quinolizidine alkaloid that comes from seeds or other plants of the Leguminosae (Fabaceae) family."( Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.
Kang, Z; Li, D; Ni, S; Qian, J; Qian, Z; Yu, B; Zhang, F; Zhong, Z; Zhou, Y, 2020
)
2.72
"Cytisine is a quinolizidine alkaloid, which has been reported to be among the major bioactive components of Sophora alopecuraides L. "( Cytisine induces apoptosis of HepG2 cells.
Chen, ZF; Ji, YB; Jiang, B; Shang, DY; Sun, YX; Wang, X; Yang, JH; Yu, L; Zhang, LF, 2017
)
3.34
"Cytisine is a plant-based smoking cessation medication with more than 50 years of use in central and eastern Europe."( The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
Boland, VC; Courtney, RJ; Doran, CM; Farrell, M; Ferguson, SG; Gartner, C; Hall, W; Mattick, RP; McRobbie, H; Mendelsohn, CP; Paul, C; Petrie, D; Richmond, R; Shakeshaft, A; Siahpush, M; Thomas, D; Tutka, P; Walker, N; West, R; Zwar, N, 2019
)
1.49
"Cytisine is a low-cost medication found to increase the likelihood of smoking cessation. "( Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
Benowitz, NL; Courtney, RJ; Tutka, P; Vinnikov, D, 2019
)
3.4
"Cytisine is an effective treatment for smoking cessation with efficacy comparable to that of other currently licensed treatments. "( Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis.
Hajek, P; McRobbie, H; Myers, K, 2013
)
2.21
"Cytisine is an alkaloid of plant origin. "( [Crystal and molecular structure of cytisine salts].
Kubicki, M; Niedźwiecka, J; Przybył, AK, 2012
)
2.1
"Cytisine (CYT) is a partial agonist of brain α4β2 nicotinic acetylcholine receptors widely used in Central/Eastern Europe for smoking cessation."( Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Florek-Łuszczki, M; Kondrat-Wróbel, MW; Tutka, P; Zaluska, K; Żółkowska, D; Łuszczki, JJ, 2017
)
3.34
"Cytisine is a low-cost, plant-based alkaloid that has been sold as a smoking cessation aid in Eastern Europe for 50 years."( Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.
Barnes, J; Bullen, C; Glover, M; Howe, C; McRobbie, H; Nosa, V; Parag, V; Veale, R; Walker, N; Williman, J, 2011
)
1.35
"Cytisine (cy) is a potent and competitive partial agonist at alpha4 subunit-containing nicotinic acetylcholine (nACh) receptors while at homomeric alpha7-nACh receptors it behaves as a full agonist with a relatively lower potency. "( Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes.
Bermúdez, I; Cassels, BK; Exley, R; Houlihan, LM; Lukas, RJ; Maskell, PD; Slater, YE; Valdivia, AC, 2003
)
2.14
"Cytisine is an agonist of nicotinic receptors; in particular, it binds strongly with alpha(4)beta(2) nicotinic receptors. "( Cytisine for smoking cessation: a literature review and a meta-analysis.
Etter, JF,
)
3.02
"Cytisine is a partial agonist with high affinity binding to the alpha4beta2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine."( An uncontrolled trial of cytisine (Tabex) for smoking cessation.
Cedzynska, M; Tutka, P; West, R; Zatonski, W, 2006
)
1.36
"[3H]Cytisine proves to be an excellent marker for nicotinic cholinergic receptors with a very high affinity and very low background."( Localization of nicotinic cholinergic receptors in rat brain: autoradiographic studies with [3H]cytisine.
Bergman, DA; Happe, HK; Murrin, LC; Peters, JL, 1994
)
0.99
"Cytisine is a nAChR agonist (EC50, approximately 46 microM) that was somewhat less efficacious than nicotine (Emax, approximately 85% of 10 microM nicotine) in adrenal chromaffin cells."( Evidence for spare nicotinic acetylcholine receptors and a beta 4 subunit in bovine adrenal chromaffin cells: studies using bromoacetylcholine, epibatidine, cytisine and mAb35.
Boyd, RT; Bryant, DL; McKay, DB; Wenger, BW, 1997
)
1.22
"Cytisine, which is a partial agonist at alpha4beta2-type receptors, produced partial seizures."( Genetic and pharmacological strategies identify a behavioral function of neuronal nicotinic receptors.
Collins, AC; Jimenez, M; Lu, Y; Stitzel, JA; Tritto, T, 2000
)
1.03

Effects

Cytisine has a molecular structure somewhat similar to that of nicotine and varenicline. It has been used to treat tobacco dependence for 40 years in Eastern Europe.

ExcerptReferenceRelevance
"Cytisine has a molecular structure somewhat similar to that of nicotine and varenicline. "( Cytisine for smoking cessation: a research agenda.
Benowitz, NL; Dresler, CM; Etter, JF; Lukas, RJ; West, R, 2008
)
3.23
"Cytisine has been shown several potential pharmacological functions."( Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.
Kang, Z; Li, D; Ni, S; Qian, J; Qian, Z; Yu, B; Zhang, F; Zhong, Z; Zhou, Y, 2020
)
2.72
"Cytisine has been in use since 1964 and is currently marketed in 18 countries. "( Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
Benowitz, NL; Courtney, RJ; Tutka, P; Vinnikov, D, 2019
)
3.4
"Cytisine has been used for several decades; yet despite its surprising popularity in some parts of the world, it has been absent from almost all existing reviews of smoking cessation drugs."( Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation.
Tutka, P, 2008
)
1.07
"Cytisine has been used to treat tobacco dependence for 40 years in Eastern Europe."( Cytisine for smoking cessation: a literature review and a meta-analysis.
Etter, JF,
)
2.3
"Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. "( An uncontrolled trial of cytisine (Tabex) for smoking cessation.
Cedzynska, M; Tutka, P; West, R; Zatonski, W, 2006
)
2.08
"Cytisine has a molecular structure somewhat similar to that of nicotine and varenicline. "( Cytisine for smoking cessation: a research agenda.
Benowitz, NL; Dresler, CM; Etter, JF; Lukas, RJ; West, R, 2008
)
3.23

Actions

Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive.

ExcerptReferenceRelevance
"Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive."( Nicotine receptor partial agonists for smoking cessation.
Cahill, K; Lancaster, T; Stead, LF, 2008
)
1.07
"Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive."( Nicotine receptor partial agonists for smoking cessation.
Cahill, K; Lancaster, T; Stead, LF, 2010
)
1.08
"Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive."( Nicotine receptor partial agonists for smoking cessation.
Cahill, K; Lancaster, T; Stead, LF, 2011
)
1.09

Treatment

Treatment with cytisine improved glucagon responses as well as epinephrine release and production in recurrently hypoglycemic animals. Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries.

ExcerptReferenceRelevance
"Cytisine (a treatment pharmacologically similar to varenicline) is also licensed for use in Russia and some of the former socialist economy countries."( Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
Cahill, K; Lancaster, T; Perera, R; Stevens, S, 2013
)
1.11
"Cytisine pretreatment (5 mg/kg s.c.) inhibited completely the radioligand accumulation in the thalamus."( Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors.
Bottlaender, M; Coulon, C; Dannals, RF; Dolle, F; Kassiou, M; Loc'h, C; Maziere, B; Musachio, JL; Ottaviani, M, 2002
)
1.04
"Treatment with cytisine is an effective, cost-efficient, affordable and well tolerated nicotine addiction therapy. "( Cytisine - From the Past to the Future.
Banach, M; Bielecka-Dąbrowa, A; Dąbrowa, M; Gąsiorek, P; Paduszyńska, A; Rysz, J, 2018
)
2.28
"Pretreatment with cytisine (0.5 or 1.5 mg/kg) significantly reduced ethanol consumption and preference in both paradigms at 2 h and 24 h post-treatment."( Cytisine modulates chronic voluntary ethanol consumption and ethanol-induced striatal up-regulation of ΔFosB in mice.
Rahman, S; Sajja, RK, 2013
)
2.16
"Treatment with cytisine improved glucagon responses as well as epinephrine release and production in recurrently hypoglycemic animals."( Partial blockade of nicotinic acetylcholine receptors improves the counterregulatory response to hypoglycemia in recurrently hypoglycemic rats.
Chan, O; Kirtok, N; LaGamma, EF; Nankova, BB, 2014
)
0.74
"Pretreatment with cytisine (0.5, 1.5 or 3.0 mg/kg) or lobeline (4.0 or 10.0 mg/kg) significantly reduced nicotine-induced increase in ethanol intake post 1 h and 2 h, without affecting water consumption."( Neuronal nicotinic receptor ligands modulate chronic nicotine-induced ethanol consumption in C57BL/6J mice.
Rahman, S; Sajja, RK, 2012
)
0.7

Toxicity

cytisine is a toxic constituent of Laburnum anagyroides Med. cytisine has been used in traditional Chinese medicine.

ExcerptReferenceRelevance
"The effect of various drugs on the acute toxicity of cytisine, the toxic constituent of Laburnum anagyroides Med, was studied in mice."( The influence of drugs on the acute toxicity of cytisine.
Damm, G; Klöcking, HP; Richter, M, 1980
)
0.77
" Each drug, besides its therapeutic effect, creates the risk of adverse reactions which number and severity is not always accepted by the patient."( [Safety of nicotine addiction treatment].
Cieślewicz, A; Jabłecka, A; Korzeniowska, K, 2013
)
0.39
" Participants will also be contacted twice (2 and 4 weeks post-randomization) to ascertain adverse events, treatment adherence and smoking status."( The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
Boland, VC; Courtney, RJ; Doran, CM; Farrell, M; Ferguson, SG; Gartner, C; Hall, W; Mattick, RP; McRobbie, H; Mendelsohn, CP; Paul, C; Petrie, D; Richmond, R; Shakeshaft, A; Siahpush, M; Thomas, D; Tutka, P; Walker, N; West, R; Zwar, N, 2019
)
0.76
" tonkinensis) held great value in the clinical application of traditional Chinese medicine, but cardiotoxic effects were reported, with matrine, oxymatrine, cytisine, and sophocarpine being the primary toxic components."( An integrated characterization of contractile, electrophysiological, and structural cardiotoxicity of Sophora tonkinensis Gapnep. in human pluripotent stem cell-derived cardiomyocytes.
Cheng, Q; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Yang, K; Ye, J; Zhou, P, 2019
)
0.71
" Adverse events were monitored."( Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.
Boonsawat, W; Dilokthornsakul, P; Hansuri, N; Lertsinudom, S; Phusahat, P; Tawinkan, N; Theeranut, A; Zaeoue, U, 2022
)
1.03
" Adverse events of cytisine were common and non-serious (registration number: TCTR20180312001)."( Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.
Boonsawat, W; Dilokthornsakul, P; Hansuri, N; Lertsinudom, S; Phusahat, P; Tawinkan, N; Theeranut, A; Zaeoue, U, 2022
)
1.36
" Administering compounds together partially reduced the adverse teratogenic effect induced by nicotine alone."( Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model.
Budzyńska, B; Chałas, R; Maciąg, M; Rahnama-Hezavah, M; Stachurski, P; Świątkowska, A; Świątkowski, W; Tylżanowski, P, 2023
)
1.28

Pharmacokinetics

ExcerptReferenceRelevance
" Since pharmacokinetic factors do not account for this discrepancy, a pharmacodynamic explanation will be necessary."( Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.
Reavill, C; Stolerman, IP; Testa, B; Walther, B, 1990
)
0.53
"The pharmacokinetic behaviour of cytisine was studied in mice by means of tritiated cytisine after intravenous and oral administration of a sublethal dose of 2 mg/kg."( Pharmacokinetic studies with 3H-cytisine.
Damm, G; Klöcking, HP; Richter, M, 1980
)
0.83
" Preliminary pharmacodynamic studies demonstrated its activity in inhibiting breast cancer cell metastasis."( Pharmacokinetics, Tissue Distribution, and Druggability Prediction of the Natural Anticancer Active Compound Cytisine N-Isoflavones Combined with Computer Simulation.
Chen, F; Lv, Y; Ouyang, S; Sheng, S; Wang, Y; Yin, X; Zhong, Y, 2020
)
0.77

Compound-Compound Interactions

Cytisine, when combined with community pharmacists' counselling, did not statistically improve the CAR at week 48. It did improve theCAR at weeks 2, 4, and 12.

ExcerptReferenceRelevance
"The aim of this study was to evaluate the efficacy of cytisine in combination with community pharmacists' counselling on smoking cessation in a community pharmacy in ThailandDesign."( Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.
Boonsawat, W; Dilokthornsakul, P; Hansuri, N; Lertsinudom, S; Phusahat, P; Tawinkan, N; Theeranut, A; Zaeoue, U, 2022
)
1.28
"Cytisine, when combined with community pharmacists' counselling, did not statistically improve the CAR at week 48, although it did improve the CAR at weeks 2, 4, and 12."( Efficacy and Safety of Cytisine in Combination with a Community Pharmacists' Counselling for Smoking Cessation in Thailand: A Randomized Double-Blinded Placebo-Controlled Trial.
Boonsawat, W; Dilokthornsakul, P; Hansuri, N; Lertsinudom, S; Phusahat, P; Tawinkan, N; Theeranut, A; Zaeoue, U, 2022
)
2.47

Bioavailability

ExcerptReferenceRelevance
" The absorption rate is approximately 42%."( Pharmacokinetic studies with 3H-cytisine.
Damm, G; Klöcking, HP; Richter, M, 1980
)
0.54
" The profiles of S-4, its N-methyl analogue, and the corresponding enantiomers across several measures of cholinergic channel function in vitro and in vivo are presented, together with in vitro metabolism and in vivo bioavailability data."( Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
Anderson, DJ; Arneric, SP; Brioni, JD; Buccafusco, JJ; Buckley, MJ; Decker, MW; Donnelly-Roberts, DL; Garvey, DS; Gunn, DE; Holladay, MW; Lin, NH; Marsh, KG; Prendergast, MA; Rodrigues, AD; Ryther, KB; Sullivan, JP; Williams, M, 1997
)
0.3
" This work is aimed at theoretical determination of physicochemical parameters that affect the bioavailability of cytisine."( Cytisine basicity, solvation, logP, and logD theoretical determination as tool for bioavailability prediction.
Grudzień, M; Mazurek, AP; Pieńko, T; Taciak, PP, 2016
)
2.09
" Systemic bioavailability from oral ingestion is high and clearance is primarily renal, with minimal or no metabolism."( Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.
Benowitz, NL; Courtney, RJ; Tutka, P; Vinnikov, D, 2019
)
1.96
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Low and high doses of NIC, cytisine (CYT), CC4 and CC26 respectively improved and worsened the mean running time. In generalization tests, rats trained with either cytisine or nicotine showed steep dose-response curves (generalization gradients) for their respective training drug.

ExcerptRelevanceReference
" For alpha 4 beta 2 receptors, 3 microM cytisine shifted the dose-response curve for ACh to the right, resulting in a 60-fold increase in the apparent EC50 for ACh."( Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.
Heinemann, SF; Papke, RL, 1994
)
0.84
" In generalization tests, rats trained with either cytisine or nicotine showed steep dose-response curves (generalization gradients) for their respective training drug."( Discriminative stimulus properties of the nicotinic agonist cytisine.
Chandler, CJ; Stolerman, IP, 1997
)
0.79
" (-)-Nicotine exhibited a bell-shaped dose-response relationship, and showed attenuation of response at the highest dose (5."( Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study.
Imoto, M; Ohno, T; Saito, K; Tani, Y, 1998
)
0.3
" Mecamylamine (1mg/kg) produced parallel rightward shifts in the dose-response curves for nicotine (3."( The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham, CS; McMahon, LR, 2011
)
0.63
" Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-administration shows an inverted-U dose-response curve."( CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Braida, D; Clementi, F; Fasoli, F; Fucile, S; Gotti, C; Grady, SR; Loi, B; Manfredi, I; Marks, MJ; Pucci, L; Sala, M; Sparatore, F; Tasso, B; Wageman, CR; Zoli, M, 2013
)
1.22
"Repeated dosing (0."( Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats.
Busto, UE; Cassels, BK; Gysling, K; Quintanilla, ME; Sotomayor-Zárate, R; Tampier, L, 2013
)
0.74
"Low and high doses of NIC, cytisine (CYT), CC4 and CC26 respectively improved and worsened the mean running time, showing an inverted U dose-response function."( Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.
Braida, D; Gotti, C; Martucci, R; Ponzoni, L; Sala, M; Sparatore, F, 2014
)
0.7
" This study examined dose-response relationships for murine α6β2*-nicotinic acetylcholine receptor (nAChR) down-regulation by chronic nicotine treatment."( α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Grady, SR; Marks, MJ; McIntosh, JM; Paley, MA; Salminen, O; Wageman, CR; Whiteaker, P, 2014
)
0.4
" Twenty-one trials of varenicline of differing dosing schedules and two trials of cytisine at standard dose met the inclusion criteria."( What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Cantrell, A; Everson-Hock, E; Leaviss, J; Ren, S; Stevens, JW; Stevenson, M; Strong, M; Sullivan, W, 2014
)
0.87
"Eligible participants will be randomized (1 : 1 ratio) to receive either cytisine capsules (25-day supply) or varenicline tablets (12-week supply), prescribed in accordance with the manufacturer's recommended dosing regimen."( The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial.
Boland, VC; Courtney, RJ; Doran, CM; Farrell, M; Ferguson, SG; Gartner, C; Hall, W; Mattick, RP; McRobbie, H; Mendelsohn, CP; Paul, C; Petrie, D; Richmond, R; Shakeshaft, A; Siahpush, M; Thomas, D; Tutka, P; Walker, N; West, R; Zwar, N, 2019
)
1
" This study evaluated the effects of a higher dosage and simplified dosing schedule on drug efficacy and tolerability."( A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial).
Benowitz, N; Clarke, A; Jacobs, C; Nides, M; Rigotti, NA, 2021
)
0.62
"5-mg 25-day titration schedule has been marketed in Central and Eastern Europe for decades, this study explored using a higher dosage and a simplified dosing schedule for impact on cytisinicline efficacy and tolerability."( A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial).
Benowitz, N; Clarke, A; Jacobs, C; Nides, M; Rigotti, NA, 2021
)
0.62
" Given the much lower cost of cytisine treatment, its lower rate of adverse events, and higher feasibility (but its likely lower effectiveness with the standard dosage regimen), future analyses should assess the cost-effectiveness of the two treatments for health policy considerations."( Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial.
Ashburner, JM; Klemenc Ketiš, Z; Oreskovic, S; Oreskovic, T; Percac-Lima, S; Rifel, J; Tiljak, H, 2023
)
2.64
" Although not licensed in the US, cytisinicline is used in some European countries to aid smoking cessation, but its traditional dosing regimen and treatment duration may not be optimal."( Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
Benowitz, NL; Blumenstein, B; Cain, D; Clarke, A; Jacobs, C; Leischow, S; Nides, M; Prochaska, J; Rigotti, NA, 2023
)
0.91
"To evaluate the efficacy and tolerability of cytisinicline for smoking cessation when administered in a novel pharmacokinetically based dosing regimen for 6 or 12 weeks vs placebo."( Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
Benowitz, NL; Blumenstein, B; Cain, D; Clarke, A; Jacobs, C; Leischow, S; Nides, M; Prochaska, J; Rigotti, NA, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
nicotinic acetylcholine receptor agonistAn agonist that selectively binds to and activates a nicotinic acetylcholine receptor.
phytotoxinAny toxin produced by a plant.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
alkaloidAny of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (49)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency18.25630.177814.390939.8107AID2147
USP1 protein, partialHomo sapiens (human)Potency99.14980.031637.5844354.8130AID504865; AID743255
Microtubule-associated protein tauHomo sapiens (human)Potency44.66840.180013.557439.8107AID1468
EWS/FLI fusion proteinHomo sapiens (human)Potency37.22120.001310.157742.8575AID1259256
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency0.06310.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.16231.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acetylcholine receptor subunit alphaHomo sapiens (human)Ki0.25000.00553.31338.2000AID254522
Acetylcholine receptor subunit alphaTetronarce californica (Pacific electric ray)Ki0.25000.00279.359634.0000AID239537
Acetylcholine receptor subunit betaTetronarce californica (Pacific electric ray)Ki0.25000.002711.753834.0000AID239537
Acetylcholine receptor subunit gammaTetronarce californica (Pacific electric ray)Ki0.25000.002711.753834.0000AID239537
Acetylcholine receptor subunit deltaTetronarce californica (Pacific electric ray)Ki0.25000.000110.074734.0000AID239537
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.10130.00000.352210.0000AID145685; AID146006; AID146162; AID264236; AID264237; AID536862
Acetylcholine receptor subunit gammaHomo sapiens (human)Ki0.25000.00553.31338.2000AID254522
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.06920.00030.30952.3000AID484912
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.09060.00000.12345.5000AID1057191; AID1057417; AID145685; AID146486; AID146772; AID1682164; AID1682166; AID1682167; AID239277; AID239312; AID264238; AID264239; AID264240; AID3056; AID488647; AID536863; AID705823; AID735358
Acetylcholine receptor subunit betaHomo sapiens (human)Ki0.25000.00553.31338.2000AID254522
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.00260.00000.04230.4500AID145685; AID145983; AID264234; AID264235
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.06920.00030.32092.3000AID484912
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.08540.00000.10825.5000AID1057191; AID1057417; AID145685; AID145983; AID146006; AID146486; AID1682164; AID1682166; AID1682167; AID239277; AID239312; AID264234; AID264236; AID264238; AID264240; AID3056; AID488647; AID536863; AID705823; AID735358
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)Ki0.00250.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Ki0.08060.00000.296310.0000AID145685; AID146162; AID146772; AID264235; AID264237; AID264239; AID536862
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)IC50 (µMol)14.02500.00110.539010.0000AID1179351; AID1179352
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)Ki0.00110.00000.11173.5400AID1179341; AID1682164; AID239394; AID254476; AID276249
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki0.00250.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit beta-4Homo sapiens (human)Ki0.76640.00010.62945.4000AID1179342; AID239374; AID239450; AID254478; AID276250; AID322470; AID735357
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)Ki0.76640.00000.65225.4000AID1179342; AID239374; AID239450; AID254478; AID276250; AID322470; AID735357
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)Ki3.83670.00221.742710.0000AID1179343; AID239283; AID254485
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki0.00250.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)Ki0.00250.00000.05250.4500AID145685
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)14.02500.00110.491110.0000AID1179351; AID1179352
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)Ki0.00110.00000.11573.5400AID1179341; AID1682164; AID239394; AID254476; AID276249
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Ki2.53440.00000.73078.0000AID1057415; AID145685; AID1682166; AID239590; AID322471; AID488648; AID705821
Acetylcholine receptor subunit deltaHomo sapiens (human)Ki0.25000.00553.31338.2000AID254522
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)Ki0.00250.00000.05250.4500AID145685
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acetylcholine receptor subunit alphaHomo sapiens (human)EC50 (µMol)0.01100.00013.337010.0000AID246397
Acetylcholine receptor subunit deltaTetronarce californica (Pacific electric ray)EC50 (µMol)100.00000.10000.16670.2000AID145357
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)EC50 (µMol)5.01250.00001.011610.0000AID145657; AID246719
Acetylcholine receptor subunit gammaHomo sapiens (human)EC50 (µMol)0.01100.00010.00550.0110AID246397
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)24.00000.01402.272410.0000AID145657; AID146297
Acetylcholine receptor subunit betaHomo sapiens (human)EC50 (µMol)0.01100.00010.00550.0110AID246397
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.10002.104010.0000AID145657
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)24.00000.01402.310410.0000AID145657; AID146297
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.04601.761010.0000AID145657
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)EC50 (µMol)5.01250.00001.010110.0000AID145657; AID246719
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)EC50 (µMol)26.75010.00001.51729.4000AID1179350; AID146297; AID240235; AID246575
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.10002.104010.0000AID145657
Adenosine receptor A2aRattus norvegicus (Norway rat)EC50 (µMol)0.00040.00000.11560.7200AID246575
Neuronal acetylcholine receptor subunit beta-4Homo sapiens (human)EC50 (µMol)26.00000.00703.454010.0000AID145356
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)EC50 (µMol)46.50000.00702.25879.4000AID145356; AID240235
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)EC50 (µMol)71.00000.12802.80188.9000AID146779; AID240211
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.04601.761010.0000AID145657
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.10002.104010.0000AID145657
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)EC50 (µMol)13.33350.00001.61869.4000AID1179350; AID146297; AID246575
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.00021.848110.0000AID145657
Acetylcholine receptor subunit deltaHomo sapiens (human)EC50 (µMol)0.01100.00010.00550.0110AID246397
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)EC50 (µMol)10.00000.10002.104010.0000AID145657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Affinity0.22000.00050.11030.2200AID243385
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Affinity0.00010.00000.00010.0001AID243384
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Affinity0.00010.00000.00010.0001AID243384
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Affinity0.22000.00050.11030.2200AID243385
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (90)

Processvia Protein(s)Taxonomy
neuromuscular synaptic transmissionAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junction developmentAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit alphaHomo sapiens (human)
neuronal action potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
muscle cell cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit alphaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit alphaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit alphaHomo sapiens (human)
response to nicotineAcetylcholine receptor subunit alphaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit alphaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit gammaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit gammaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit gammaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit gammaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit gammaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit gammaHomo sapiens (human)
postsynaptic membrane organizationAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit betaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit betaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit betaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit betaHomo sapiens (human)
neuromuscular synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit betaHomo sapiens (human)
behavioral response to nicotineAcetylcholine receptor subunit betaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
nervous system processAcetylcholine receptor subunit betaHomo sapiens (human)
muscle cell developmentAcetylcholine receptor subunit betaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit betaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit betaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit betaHomo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual perceptionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of soundNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
associative learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
vestibulocochlear nerve developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
optic nerve morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
lateral geniculate nucleus developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
central nervous system projection neuron axonogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of B cell proliferationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synaptic transmission, dopaminergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
social behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine metabolic processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to cocaineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of circadian sleep/wake cycle, REM sleepNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to ethanolNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
negative regulation of action potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synapse assemblyNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuronal action potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of neurotransmitter secretionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
positive regulation of transmission of nerve impulseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nervous system developmentNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of acetylcholine secretion, neurotransmissionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
action potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
DNA repairNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to oxidative stressNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit deltaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit deltaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit deltaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit deltaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit deltaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit deltaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit deltaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit deltaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
acetylcholine receptor activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
protein bindingAcetylcholine receptor subunit gammaHomo sapiens (human)
channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingAcetylcholine receptor subunit betaHomo sapiens (human)
channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
ligand-gated monoatomic ion channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit betaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein-containing complex bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
protein bindingNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit deltaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
cell surfaceAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit alphaHomo sapiens (human)
synapseAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit gammaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
synapseAcetylcholine receptor subunit gammaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit gammaHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
presynaptic membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
specific granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
tertiary granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
endoplasmic reticulumNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
Golgi apparatusNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic densityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nuclear speckNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
neuromuscular junctionAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit deltaHomo sapiens (human)
synapseAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (174)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1682169Displacement of [3H]QNB from Sprague-Dawley rat brain Muscarinic acetylcholine receptor2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID243949Percent antagonist activity against 10 uM nicotine at human nicotinic acetylcholine receptor alpha4-beta2 at 10 uM2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID484912Displacement of [3H]epibatidine from rat alpha4beta2 nAChR2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
In silico characterization of cytisinoids docked into an acetylcholine binding protein.
AID1057189Displacement of [3H]methyllycaconitine from Sprague-Dawley rat brain alpha7 nAChR after 120 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs.
AID251184Percentage efficacy in TE671 cells expressing acetylcholine neuromuscular receptor as change in membrane potential2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID240237Effective concentration against Nicotinic acetylcholine receptor alpha4-beta2 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID276253Selectivity for human alpha-4-beta-2 nAChR over human alpha3beta4 nAChR2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Epibatidine isomers and analogues: structure-activity relationships.
AID1057416Binding affinity to pig adrenal alpha3beta4 nAChR by radioligand displacement assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents.
AID3056In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
3D QSAR analyses-guided rational design of novel ligands for the (alpha4)2(beta2)3 nicotinic acetylcholine receptor.
AID337605Displacement of [3H]quinuclidinyl benzilate from muscarinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID231914Ratio between the binding affinities towards rat alpha3-beta4 and forebrain nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID239537Inhibition of [125I]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha1 beta gamma delta of electroplax2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID337604Displacement of [3H]nicotin from nicotinic ACh receptor1994Journal of natural products, Sep, Volume: 57, Issue:9
Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors.
AID246575Change in membrane potential in K-177 cells expressing acetylcholine central neuronal receptor alpha4-beta2 subunits 2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID146162Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta4 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID242878Maximal response against Nicotinic acetylcholine receptor alpha4-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID264237Displacement of [3H]epibatidine from rat alpha3beta4 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID264238Displacement of [3H]epibatidine from rat alpha-4-beta-2 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID239394Binding affinity against nicotinic acetylcholine receptor alpha4-beta2 in human HEK293 cells using [3H]- nicotine as radioligand2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID264235Displacement of [3H]epibatidine from rat alpha-2-beta-4 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID1410568Toxicity in iv dosed albino mouse measured after 1 hr2018Journal of natural products, 04-27, Volume: 81, Issue:4
Absolute Configuration and Pharmacology of the Poison Frog Alkaloid Phantasmidine.
AID243426Percent agonist activity relative to 10 uM (-)-nicotine at human nicotinic acetylcholine receptor alpha4-beta2 at 10 uM2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID322471Displacement of [125I]alpha-bungarotoxin from rat alpha7 nAChR in GH4C1 cells2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine.
AID146478In vitro binding affinity by inhibiting [3H]dopamine release in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta22002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Synthesis and biological evaluation at nicotinic acetylcholine receptors of N-arylalkyl- and N-aryl-7-azabicyclo[2.2.1]heptanes.
AID1682167Displacement of [3H]nicotine from rat alpha4beta2 nAChR by liquid scintillation counting2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID276250Displacement of [3H]epibatidine from human recombinant alpha-3-beta-4 nAChR in HEK293 cells by SPA assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Epibatidine isomers and analogues: structure-activity relationships.
AID1682173Binding affinity to Sprague-Dawley rat brain nAChR assessed as maximum binding density using radiolabelled compound incubated for 75 min by scatchard analysis2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID239277Inhibition of [3H]-nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 in rat cortex2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID225720Binding affinity towards rat alpha2-beta4 nACh receptor expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID242872Maximal response against Nicotinic acetylcholine receptor alpha 72005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID256206Efficacy against human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM relative to 10 uM nicotine2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID1682170Displacement of [3H]Cytisine from Sprague-Dawley rat brain nAChR2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID488647Displacement of (+/-)-[3H]epibatidine from alpha4beta2 nAChR in rat cortical membrane2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Novel tricyclic Delta(2)-isoxazoline and 3-oxo-2-methyl-isoxazolidine derivatives: synthesis and binding affinity at neuronal nicotinic acetylcholine receptor subtypes.
AID397986Displacement of (+/-)-[3H]epibatidine from alpha4beta2 nicotinic acetylcholine receptor in rat brain cortex membrane homogenates2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Synthesis, binding, and modeling studies of new cytisine derivatives, as ligands for neuronal nicotinic acetylcholine receptor subtypes.
AID735356Displacement of [125I]alpha-bungarotoxin from alpha7 nAChR from rat hippocampus2013Journal of natural products, Apr-26, Volume: 76, Issue:4
(+)-Laburnamine, a natural selective ligand and partial agonist for the α4β2 nicotinic receptor subtype.
AID175480Compound was evaluated for functional potencies and efficacies at rat nAChR subtype DA release1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID242877Maximal response against Nicotinic acetylcholine receptor alpha4-beta22005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID1179343Partial agonist activity at alpha7 nAChR (unknown origin)2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID1160744Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID527074Displacement of [3H]cytisine from rat alpha4beta2 nAChR in rat brain cell membrane2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Identification of 9-fluoro substituted (-)-cytisine derivatives as ligands with high affinity for nicotinic receptors.
AID146006Binding affinity towards rat Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID536862Displacement of [3H]epibatidine from rat alpha3beta4 nAChR expressed in HEK292 cells after 3 hrs2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.
AID276249Displacement of [3H]epibatidine from human recombinant alpha4beta2 nAChR in HEK293 cells by SPA assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Epibatidine isomers and analogues: structure-activity relationships.
AID146317Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor alpha4-beta2; low efficacy1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID242876Maximal response against Nicotinic acetylcholine receptor alpha3-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID264234Displacement of [3H]epibatidine from rat alpha-2-beta-2 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID145357Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor subtype TE671 (muscle)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID239450Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of IMR32 cells2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID231915Ratio between the binding affinities towards rat alpha4-beta4 and alpha4-beta2 nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID240234Effective concentration against Nicotinic acetylcholine receptor alpha2-beta4 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID239283Inhibition of [3H]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha7 of IMR32 cells2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID242875Maximal response against Nicotinic acetylcholine receptor alpha3-beta22005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID254478Binding affinity to human Nicotinic acetylcholine receptor alpha3-beta4 expressed in IMR32 cells using [3H]epibatidine2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID240211Effective concentration against Nicotinic acetylcholine receptor alpha 7 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID242874Maximal response against Nicotinic acetylcholine receptor alpha2-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID1179350Activation of alpha4beta2* nAChR high affinity site (unknown origin) expressed in xenopus oocytes by electrophysiology method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID1682174Binding affinity to Sprague-Dawley rat brain nAChR incubated for 75 min by scatchard analysis2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID231911Ratio between the binding affinities towards rat alpha2-beta4 and alpha2-beta2 nACh receptor using [3H]-EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID231912Ratio between the binding affinities towards rat alpha3-beta4 and alpha3-beta2 nACh receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID239312Inhibition of [3H]nicotine binding to nicotinic acetylcholine receptor alpha4-beta2 of rat cortex2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID1682168Neuroprotective activity in Sprague-Dawley rat assessed as dopamine expression in substantia nigra at 2 mg/kg, sc administered 4 hrs prior to 6-OHDA injection and 20 to 68 hrs post 6-OHDA injection and measured 8 days post 6-OHDA injection by microdialysi2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1057191Displacement of [3H]epibatidine from Sprague-Dawley rat brain alpha4beta2 nAChR after 90 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs.
AID242894Maximal response against Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID251198Percentage efficacy in KXalpha-3-beta-4R2 cells expressing rat nicotinic acetylcholine receptor alpha-3 beta4 subunits relative to (1)-epibatidine2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID264236Displacement of [3H]epibatidine from rat alpha-3-beta-2 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID1057415Displacement of [3H]methyllycaconitine from rat forebrain alpha7 nAChR2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents.
AID705823Binding affinity to rat alpha4beta2 nAChR2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: a novel class of highly potent nicotinic receptor ligands.
AID240238Effective concentration against Nicotinic acetylcholine receptor alpha4-beta4 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID146772Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta4 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1682164Displacement of [3H]cytisine from human alpha4beta2 nAChR by Cheng-Prusoff equation analysis2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID322469Displacement of [3H]nicotine from alpha4beta2 nAChR in Sprague-Dawley rat brain membrane2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine.
AID251221Percent response relative to 10 uM nicotine in human Nicotinic acetylcholine receptor alpha4-beta22005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID239590Inhibition of [125I]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha-7 subunit in rat GH4C1 cells2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID147082In vitro binding affinity towards Nicotinic acetylcholine receptor alpha7 using [125I]-alpha-Bungarotoxin in rat brain2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization.
AID146297Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor alpha4-beta21997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID1057414Binding affinity to (alpha1)2beta1gammadelta nAChR in Torpedo californica electroplax by radioligand displacement assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents.
AID239475Inhibition of [3H]alpha-bungarotoxin binding to nicotinic acetylcholine receptor alpha-1-beta-1-delta-gamma of electroplax2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID397988Displacement of [3H]cytisine from alpha4beta2 nicotinic acetylcholine receptor in rat brain cortex membrane homogenates2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Synthesis, binding, and modeling studies of new cytisine derivatives, as ligands for neuronal nicotinic acetylcholine receptor subtypes.
AID145657Compound was evaluated for functional potencies and efficacies at rat Nicotinic acetylcholine receptor subtype PC12 (ganglionic)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID536863Displacement of [3H]epibatidine from rat alpha4beta2 nAChR expressed in HEK292 cells after 3 hrs2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.
AID242892Maximal response against Nicotinic acetylcholine receptor alpha3-beta2 expressed in HEK293 cells2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID264241Selectivity for rat alpha-4-beta-2 nACHR over alpha3beta4 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID1179341Partial agonist activity at alpha4beta2 nAChR (unknown origin)2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID254485Binding affinity to human Nicotinic acetylcholine receptor alpha7 expressed in IMR32 cells using [3H]alpha-bungarotoxin2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID251953Percent inhibition of 10 uM nicotine response in human Nicotinic acetylcholine receptor alpha4-beta22005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
AID14400Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID527075Displacement of [125I]alpha-Bungarotoxin from alpha7 nAchR in rat brain cell membrane2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Identification of 9-fluoro substituted (-)-cytisine derivatives as ligands with high affinity for nicotinic receptors.
AID322470Displacement of [3H]epibatidine from human alpha3beta4 nAChR in IMR32 cells2008Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7
Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine.
AID145356Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor subtype IMR-32 (ganglionic)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID240235Effective concentration against Nicotinic acetylcholine receptor alpha3-beta2 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID243385Binding affinity (Ki) for rat nicotinic acetylcholine receptor alpha3-beta4 subunits versus 0.5 nM [3H](1)-epibatidine2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID1682166Displacement of [3H]MLA from rat alpha7 nAChR by liquid scintillation counting2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Pyridine alkaloids with activity in the central nervous system.
AID1179352Inactivation of alpha4beta2* nAChR high affinity site (unknown origin) expressed in xenopus oocytes by electrophysiology method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID239374Inhibition of [3H]epibatidine binding to nicotinic acetylcholine receptor alpha3-beta4 of human IMR32 cells2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
AID735357Displacement of [3H]epibatidine from human alpha3beta4 nAChR expressed in HEK cells2013Journal of natural products, Apr-26, Volume: 76, Issue:4
(+)-Laburnamine, a natural selective ligand and partial agonist for the α4β2 nicotinic receptor subtype.
AID251197Percentage efficacy in K-177 cells expressing acetylcholine central neuronal receptor type alpha-4 beta2 subunits as change in membrane potential2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID735355Displacement of [125I]alpha-bungarotoxin from human alpha2betagammadelta nAChR2013Journal of natural products, Apr-26, Volume: 76, Issue:4
(+)-Laburnamine, a natural selective ligand and partial agonist for the α4β2 nicotinic receptor subtype.
AID488648Displacement of [125I]alpha-Bungarotoxin from alpha7 nAChR in rat cortical membrane2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Novel tricyclic Delta(2)-isoxazoline and 3-oxo-2-methyl-isoxazolidine derivatives: synthesis and binding affinity at neuronal nicotinic acetylcholine receptor subtypes.
AID705821Binding affinity to rat alpha7 nAChR2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: a novel class of highly potent nicotinic receptor ligands.
AID1057187Displacement of [3H]epibatidine from Torpedo californica electroplax (alpha1)2beta1gammadelta nAChR after 90 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs.
AID1179351Inactivation of alpha4beta2* nAChR low affinity site (unknown origin) expressed in xenopus oocytes by electrophysiology method2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID14399Biodistribution in rat cerebellum, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID256387Percent inhibition against 10 uM nicotine binding to human Nicotinic acetylcholine receptor alpha4-beta2 expressed in Xenopus oocytes at 10 uM2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID1179348Activation of alpha4beta2* nAChR high affinity site (unknown origin) expressed in xenopus oocytes by electrophysiology method relative to acetylcholine2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID254522Binding affinity to human Nicotinic acetylcholine receptor alpha-1-beta-gamma-delta expressed in HEK 293 cells using [3H]alpha-bungarotoxin2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID246397Change in membrane potential in TE-671 cells expressing acetylcholine neuromuscular receptors2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID146630in vitro binding affinity by inhibiting [3H]cytisine binding in rat brain tissue at Nicotinic acetylcholine receptor alpha4-beta22002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Synthesis and biological evaluation at nicotinic acetylcholine receptors of N-arylalkyl- and N-aryl-7-azabicyclo[2.2.1]heptanes.
AID264239Displacement of [3H]epibatidine from rat alpha-4-beta-4 nACHR expressed in human HEK293 cells2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID264240Displacement of [3H]epibatidine from rat forebrain alpha4beta2 nACHR2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity.
AID1057190Displacement of [3H]epibatidine from calf adrenal alpha3beta4 nAChR after 90 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor ligands. Part 2: carboxamide derivatives with different spacer motifs.
AID146486Binding affinity towards rat Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID240236Effective concentration against Nicotinic acetylcholine receptor alpha3-beta4 expressed in xenopus oocytes2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID1057417Displacement of [3H]-epibatidine from rat forebrain alpha4beta2 nAChR2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
The 3,7-diazabicyclo[3.3.1]nonane scaffold for subtype selective nicotinic acetylcholine receptor (nAChR) ligands. Part 1: the influence of different hydrogen bond acceptor systems on alkyl and (hetero)aryl substituents.
AID14401Biodistribution in rat thalamus, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID735358Displacement of [3H]epibatidine from alpha4beta2 nAChR in rat cortex2013Journal of natural products, Apr-26, Volume: 76, Issue:4
(+)-Laburnamine, a natural selective ligand and partial agonist for the α4β2 nicotinic receptor subtype.
AID397987Displacement of [125I]alpha-bungarotoxin from alpha7 nicotinic acetylcholine receptor in rat brain cortex membrane homogenates2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Synthesis, binding, and modeling studies of new cytisine derivatives, as ligands for neuronal nicotinic acetylcholine receptor subtypes.
AID1160745Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Identification and synthesis of quinolizidines with anti-influenza a virus activity.
AID1179342Partial agonist activity at alpha3beta4 nAChR (unknown origin)2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID146613In vitro binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 using [3H]cytisine in rat brain2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization.
AID246719Effective concentration in KXalpha-3-beta-4R2 cells expressing rat nicotinic acetylcholine receptor alpha3-beta4 subunits2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID145685Binding affinity towards rat forebrain nicotinic acetylcholine receptor using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID243384Binding affinity (Ki) for rat brain nicotinic receptors ganglionic-type alpha-4 and beta2 subunits versus 0.5 nM [3H](1)-epibatidine2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors.
AID145983Binding affinity towards rat nicotinic acetylcholine receptor alpha2-beta2 expressed in HEK293 cells using [3H]EB as radioligand2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells.
AID254476Binding affinity for human Nicotinic acetylcholine receptor alpha4-beta2 expressed in HEK 293 cells using [3H]nicotine2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation.
AID146779Compound was evaluated for functional potencies and efficacies at human Nicotinic acetylcholine receptor alpha71997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (506)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (7.11)18.7374
1990's133 (26.28)18.2507
2000's140 (27.67)29.6817
2010's140 (27.67)24.3611
2020's57 (11.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.56 (24.57)
Research Supply Index6.29 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index128.38 (26.88)
Search Engine Supply Index3.28 (0.95)

This Compound (48.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (3.66%)5.53%
Reviews34 (6.55%)6.00%
Case Studies6 (1.16%)4.05%
Observational2 (0.39%)0.25%
Other458 (88.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]